Perspective

iMedPub Journals
www.imedpub.com

Journal of Immunology and Immunotherapy

2021
Vol.5 No.5:24

Hyperglycemia and Parkinson's Disease: A Discussion

Eden Phillips*

Editorial office, The Journal of Immunology and Immunotherapy, United Kingdom

Received: October 12, 2021; **Accepted:** October 14, 2021; **Published:** October 25, 2021

Corresponding author: Eden Phillips

jmso@emedicinejournals.org

Editorial office, The Journal of Immunology and Immunotherapy, United Kingdom.

Citation: Phillips E (2021) Hyperglycemia and Parkinson's Disease: A Discussion. J Immuno Immnother. Vol.5 No.5:24

Perspective

Parkinson's Disease (PD), often known as Parkinson's, is a long-term neurological degenerative condition that affects the engine structure. As the illness progresses, the symptoms become more noticeable, and nonengine side effects become more common. The infection's main symptoms are caused by cells moving through the substantia nigra, a midbrain area that causes a dopamine shortage. Glucose is a simple sugar that is found in most dietary carbohydrates and serves as the body's primary source of energy. Insulin is a hormone produced by the pancreas that regulates glucose levels in the body. It allows cells to absorb glucose from the blood in a variety of ways. The body is unable to supply insulin in type I diabetes. Patients with type I diabetes would essentially starve to death before insulin became available as an injectable medication, unable to utilize the glucose in their blood to supply energy.

The body generates insulin in type II diabetes, but the cells are unable to use it properly, resulting in blood glucose levels that are higher than they should be. Insulin blockage is the medical term for this physiologic condition. When blood glucose levels are consistently excessively high, small veins in various organs might be damaged. The kidneys and the eyes may be harmed as a result of this. Type 2 diabetes (T2D), often known as adult-onset diabetes, is characterized by excessive glucose levels, insulin resistance, and the lack of insulin. Type 2 diabetes is one of the world's most common and rapidly progressing disorders, and it causes a slew of problems. Patients with type 2 diabetes have a greater risk of coronary artery disease than those without the disease. High glucose levels, on the other hand, can damage cerebral veins, increasing the risk of stroke. Its belongings, on the other hand, are felt far more widely. Numerous neuronal cycles are influenced by high glucose and insulin resistance, which causes irritation in the cerebrum.

Type 2 diabetes also appears to increase the risk of Alzheimer's disease and other dementias. Type 2 diabetes is completely linked to a variety of hyperglycemia-induced disorders in nearly all organs, including mental issues such as diabetic neuropathy, stroke, dementia, and Alzheimer's disease. Diabetes may increase the risk of Parkinson's disease.

Diabetes can exacerbate Parkinson's synaptic dysfunction by causing oxidative pressure, which occurs when toxic byproducts of cell reactions, known as free radicals, begin to accumulate. Type 2 diabetes can induce vascular disease, which can lead to a reduction in blood flow to the brain, hastening the onset of Parkinson's disease. Both are characterized by abnormal protein buildup, lysosomal and mitochondrial dysfunction, and continuous fundamental inflammation. Amylin, a brain endocrine molecule, clumps together and kills neurons, which might explain why people with type 2 diabetes have a twofold increased risk of Parkinson's disease.

According to all reports, there appears to be a link between mitochondrial dysfunction and precipitous falls, as well as insulin signaling pathways that are relevant to both diseases. This has been formally studied using network-based techniques, which demonstrate that the genetic risks associated with the two illnesses are adequately covered. The idea that insulin flagging/insulin resistance may be related to neurodegeneration is gaining popularity. Insulin receptor mRNA is lost in the substantia nigra of Parkinson's disease patients before dopaminergic neurons die. Parkinson's disease development or progression has been connected to the use of some diabetes medications.

Exenatide, a diabetic medicine of the GLP1 agonist family, enhanced Parkinson's disease symptoms in patients. Blood sugar levels that are slightly high or fluctuate may raise the risk of Parkinson's disease. The distribution of two randomized PD preliminary of exenatide, a Glucagon-Like Peptide 1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes, provides the most solid indication that a specific adversary of diabetic medicines may aid in the treatment of Parkinson's disease. Neurotrophic effects are shown with these GLP-1 receptor agonists. The initial inquiry was an open-ended preliminary that left it vulnerable to self-inflicted repercussions. This demonstrated that a year of exenatide therapy addressed both engine and psychological PD shortfalls.

